Donate

Prostate Cancer Information

What is Prostate Cancer?

Prostate cancer starts when cells in the prostate (a small gland below the bladder) grow in an uncontrolled way. Many prostate cancers grow slowly, and when found early (confined to the prostate), they are highly treatable with excellent long‑term survival. Prostate cancer is the #2 most commonly diagnosed cancer in men worldwide.

 

  • Global burden (2022): ~1.47 million new cases and ~397,000 deaths. Rates vary by region, with especially high mortality in settings where late diagnosis is common. [1–3]
  • Why early detection matters: Localized disease has near‑100% 5‑year survival, whereas distant (metastatic) disease survival is much lower—one reason screening talks are emphasized for higher‑risk groups. [4–6]

Symptoms & Risk Factors

Common Symptoms (often no symptoms early)

  • Often silent in early stages. When present: urinary frequency/urgency, weak stream, difficulty starting/stopping urination, blood in urine or semen, bone pain (if spread), unintentional weight loss. These symptoms can also be caused by non‑cancer conditions; evaluation is important. [3, 7]

Major Risk Factors

  • Age: Risk rises markedly after 50. Most diagnoses occur after 60. [7–9]
  • Race/Ancestry: Black men (including men of African descent globally) have higher incidence and ~2× mortality compared with White men; causes include biologic differences and social determinants (access to care, information, environment). [10–13]
  • Family history & genetics: A first‑degree relative (father/brother) with prostate cancer increases risk. Germline variants in BRCA2, BRCA1, HOXB13 and certain DNA‑repair genes raise risk and may be linked to more aggressive disease; an African‑ancestry HOXB13 mutation (X285K) has been associated with aggressive prostate cancer. [11, 14–16]
  • Other factors (still under study): Obesity, limited physical activity, and some diet patterns may influence risk or progression; evidence for prevention is mixed (see Prevention Tips). [17–19]

Diagnosis & Screening

Screening (finding cancer early)

  • Core tests:
    • PSA blood test – first‑line screening tool. [20]
    • Digital Rectal Exam (DRE) – optional adjunct to feel for abnormalities. [20]
  • When to start the conversation:
    • Black men & those with family history:
      • ACS: talk about screening at age 45 (earlier if multiple relatives diagnosed young). [20]
      • PCF expert panel (2024, NEJM Evidence): consider a baseline PSA at 40–45 and regular screening to ~70, using shared decision‑making. [21–23]
    • Average risk: ACS recommends discussion at 50 if life expectancy ≥10 years. [20]
    • USPSTF (2018, current as of today): shared decision‑making for ages 55–69; against routine screening ≥70. [24]

For Black men: Because prostate cancer tends to occur younger and be more aggressive, many experts support earlier baseline PSA (40–45) plus regular follow‑up based on your PSA trend and risk profile. [21–23]

Risk‑adapted pathways (reducing unnecessary biopsies)

  • If PSA is elevated or rising, clinicians may repeat PSA and use risk calculators, percent‑free PSA, MRI, or urine/blood biomarkers before biopsy. Pre‑biopsy MRI is now standard in many guidelines to improve detection of clinically significant cancer and avoid some biopsies. [23, 25–28]

Diagnosis

  • Only a biopsy confirms cancer. Modern care often combines MRI‑targeted and systematic cores, using transperineal or transrectal approaches. Discuss potential risks (infection, bleeding) and benefits with your provider. [29–31]

References (Diagnosis & Screening ):

[20] ACS – Early detection recommendations (revised Nov 22, 2023). <https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html>
[21] PCF screening guidelines for Black men (2024). <https://www.pcf.org/…/screening-guidelines-for-black-men/>
[22] UCLA Health/ASCO GU coverage – baseline PSA 40–45 for Black men. <https://www.uclahealth.org/news/article/prostate-cancer-screenings-encouraged-black-men-early-40>
[23] Urology Times (2024) – PCF panel guideline summary; emphasis on PSA first, baseline 40–45. <https://www.urologytimes.com/view/experts-develop-guidelines-for-prostate-cancer-screening-in-black-men>
[24] USPSTF final statement (2018) – shared decision-making 55–69; discourage ≥70. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening>
[25] NCCN Early Detection (2024 updates) – MRI pre‑biopsy recognized; risk‑adapted intervals. <https://grandroundsinurology.com/update-of-changes-in-the-early-detection-of-prostate-cancer-nccn-guidelines-2024/>
[26] EAU 2024/2025 – risk‑adapted screening with PSA + calculators + MRI. <https://uroweb.org/guidelines/prostate-cancer>
[27] EAU 2024 session write‑ups (risk‑adapted algorithms). <https://www.urotoday.com/…/the-eau-screening-algorithm.html>
[28] AAFP (2024) – after elevated PSA: repeat PSA, MRI/biomarkers, urology referral. <https://www.aafp.org/pubs/afp/issues/2024/1100/prostate-cancer-screening.pdf>
[29] ACS – “Tests to diagnose and stage” (biopsy is definitive). <https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html>
[30] Johns Hopkins – diagnosis & MRI‑targeted biopsy. <https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/prostate-cancer-diagnosis>
[31] MD Anderson – biopsy approaches; what to expect.

Prevention Tips

There is no guaranteed way to prevent prostate cancer, but healthy choices can support overall wellness and may improve outcomes after diagnosis.

  • Stay active: Regular physical activity is linked with better quality of life during/after treatment and has been associated with lower prostate‑cancer and all‑cause mortality among survivors. Aim for aerobic + resistance each week. [18, 19, 38]
  • Healthy weight, balanced diet: Maintaining healthy body weight is advised; WCRF notes links between body fatness and advanced prostate cancer. Focus on whole grains, vegetables, fruits, legumes; limit highly processed foods and excess calories. Evidence on specific foods/supplements (e.g., selenium, lycopene) is inconclusive for prevention. [17, 38, 39]
  • Don’t smoke; moderate alcohol: General cancer‑prevention guidance applies. [39]
  • Know your family history & genetics: If you have multiple relatives with prostate/breast/ovarian/pancreatic cancers—especially at young ages—ask about genetic counseling/testing. Results may influence screening timing and treatment (e.g., PARP inhibitors for BRCA mutations). [14, 32–34]

Treatment Options

Choice of treatment depends on stage, risk group (very low/low, intermediate—favorable/unfavorable, high/very high), overall health, and preferences. Multidisciplinary care is essential. [32–34]

Localized (confined to prostate)

  • Active Surveillance (regular PSA/MRI/biopsy) for very low/low‑risk cancers to avoid or delay side effects; curative therapies remain available if the cancer changes. [32–35]
  • Surgery (radical prostatectomy) or Radiation therapy (external beam and/or brachytherapy) are standard curative options for intermediate to high‑risk localized disease. [32–34]

Locally Advanced / High‑Risk

  • Often requires combined therapy, e.g., radiation + androgen‑deprivation therapy (ADT); or surgery with possible adjuvantradiation/ADT depending on pathology. [32–34]

Advanced / Metastatic

  • Systemic therapies: ADT, androgen‑receptor–targeted agents, chemotherapy (e.g., docetaxel), and PARP inhibitors for men with certain DNA‑repair gene mutations (e.g., BRCA1/2). PSMA‑targeted radioligand therapy may be an option in specific settings per guideline updates. [32–34]

Side Effects & Quality of Life

  • Potential issues include urinary incontinence and erectile dysfunction after surgery; bowel/urinary symptoms with radiation; fatigue, metabolic effects, and sexual side effects with long‑term hormone therapy. Shared decision‑making and survivorship care plans are crucial. [36, 37]

FAQs

  • Black men / high‑risk (e.g., strong family history): Discuss screening by age 45 (ACS). PCF experts recommend a baseline PSA at 40–45 and regular follow‑up to ~70. [20–23]
  • Average risk: Discuss at 50 if life expectancy ≥10 years (ACS). USPSTF: shared decision‑making 55–69; no routine screening ≥70. [20, 24]
There’s no single cutoff that rules cancer in or out. Many doctors use ~4 ng/mL as a threshold to investigate, but age, PSA trend, PSA density, and MRI matter. If PSA is borderline, clinicians often repeat PSA and consider MRI/biomarkers before biopsy.
Not always. Pathways increasingly use repeat PSA, risk calculators, %free PSA, MRI, and biomarkers to decide on biopsy and to target sampling if needed.
Facebook Twitter Youtube